Considerations for drug development in hematological oncology

At the 20th Congress of the European Hematology Association (EHA), Matti Aapro, MD, of Clinique de Genolier, Genolier, Switzerland, highlights the progress of novel therapeutic agents and approaches in the field of hematological oncology and the need to find a balance between health care affordability and profits that will allow this continued innovation.

Share this video  
12th June 2015